This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Law, M., Hetzel, M. & Idel, J. Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 59, 686–687 (1989). https://doi.org/10.1038/bjc.1989.142
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.142
This article is cited by
-
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta- analysis
European Journal of Clinical Pharmacology (1997)
-
Molecular genetics of cytochrome P450 IID
Clinical Reviews in Allergy and Immunology (1995)
-
Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer
European Journal of Clinical Pharmacology (1991)
-
Metabolism of debrisoquine and susceptibility to breast cancer
Breast Cancer Research and Treatment (1991)